Skip to main content

Kaposi Sarcoma

Kasey M. Reed, MD Reviewed 06/2021
 


BASICS

Kaposi sarcoma (KS) was originally described in 1872 by a Hungarian dermatologist named Moritz Kaposi. 

DESCRIPTION

  • Synonym(s): KS; multiple idiopathic hemangiosarcoma

  • KS is a low-grade vascular t...

DIAGNOSIS

HISTORY

  • Cutaneous involvement is most common.

  • Other possible presentations include mucosal and visceral involvement and tumor-associated lymphedema with lower extremity and/or facial swelling.

  • ...

TREATMENT

The major goals of treatment are symptom palliation, prevention of disease progression, and shrinkage of tumor to alleviate edema, organ compromise, and psychological stress. 

GENERAL MEASURES

ONGOING CARE

FOLLOW-UP RECOMMENDATIONS

Patient Monitoring

  • In HIV patients with KS, other opportunistic infections must be treated aggressively.

  • Because non–AIDS-defining malignancies are becoming more co...

REFERENCES

1
Cesarman E, Damania B, Krown SE, Martin J, Bower M, Whitby D. Kaposi sarcoma. Nat Rev Dis Primers. 2019 Jan 31;5(1):9. 
2
Di Lorenzo  G, Konstantinopoulos  PA, Pantano...

ADDITIONAL READING

  • Anglemyer  A, Agrawal  AK, Rutherford  GW. Treatment of Kaposi sarcoma in children with HIV-1 infection. Cochrane Database Syst Rev.  2014;(1):CD0098...

CODES

ICD10

  • C46.5 Kaposi's sarcoma of lung

  • C46.7 Kaposi's sarcoma of other sites

  • C46 Kaposi's sarcoma

  • C46.50 Kaposi's sarcoma of unspecified lung

  • C46.4 Kaposi's sarcoma of gastrointestinal sites

  • C46.51 Kapo...

CLINICAL PEARLS

  • HHV-8 (also known as KSHV) is the etiologic agent of KS.

  • HHV-8, immunocompromised status, and cytokine-induced growth represent preconditions for the development of KS.

  • HAART is recommen...

Subscribe to Access Full Content

Sign Up for a 10-Day Free Trial

Sign up for a 10-day FREE Trial now and receive full access to all content.

 
×